CBS 2019
CBSMD教育中心
中 文

Transcatheter Aortic Valve Replacement

Abstract

Recommended Article

A Controlled Trial of Rivaroxaban After Transcatheter Aortic-Valve Replacement Valve‐in‐Valve for Degenerated Transcatheter Aortic Valve Replacement Versus Valve‐in‐Valve for Degenerated Surgical Aortic Bioprostheses: A 3‐Center Comparison of Hemodynamic and 1‐Year Outcome Minimalist transcatheter aortic valve replacement: The new standard for surgeons and cardiologists using transfemoral access? Transcatheter Aortic Valve Replacement in Patients With Multivalvular Heart Disease Reduced Leaflet Motion after Transcatheter Aortic-Valve Replacement Determinants and Impact of Heart Failure Readmission Following Transcatheter Aortic Valve Replacement Prognostic implications of baseline 6‐min walk test performance in intermediate risk patients undergoing transcatheter aortic valve replacement 2-Year Outcomes After Transcatheter Versus Surgical Aortic Valve Replacement in Low-Risk Patients
|<<... 11 12 13 14 15 16 17 ...>>|

Clinical Trial4 Apr 2022

JOURNAL：Circulation. Article Link

Edoxaban versus Dual Antiplatelet Therapy for Leaflet Thrombosis and Cerebral Thromboembolism after TAVR: The ADAPT-TAVR Randomized Clinical Trial

D-W Park, J-M Ahn, D-Y Kang et al. Keywords: TAVR; without an indication for long-term anticoagulation; subclinical leaflet thrombosis

Full Text PDF

>CBS CBS 2019

> CBS 2019 REGISTRATION

> CBS 2019 PROGRAM

> CBS 2019 CALL FOR SCIENCE

> CBS 2019 SPOTLIGHTS

 CBSMD

> CBSMD WEBSITE REGISTRATION

> EDUCATION CENTER

> RECOMMANDED PAPER

> TOP 10 RESEARCH PAPER

> PRE-READING

CBS 2019 CBS 2019 FACULTY Education Resource CBSMD Scientific Library
Copyright ⓒ CBS MD Nanjing China. All rights reserved. 京ICP备16025898号-11
联系我们| Top